Associated Papers
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
The shifting landscape of germline RET pathogenic variants with the introduction of panel testing.
Onuma AE et al.
Surgery, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.
West CE et al.
Jama Network Open, 2025
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature.
Casalini R et al.
Endocrine, 2025
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Hamidi S et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Genotype-phenotype correlations of germline mutations in exon 10 of the RET proto-oncogene from 14 MEN2A families of Ethnic Han Chinese.
Li F et al.
Plos One, 2025
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
Current prospects of hereditary adrenal tumors: towards better clinical management.
Ohmoto A et al.
Hereditary Cancer in Clinical Practice, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Integrated proteogenomic characterization of medullary thyroid carcinoma.
Shi X et al.
Cell Discovery, 2022
Are transient protein-protein interactions more dispensable?
Ghadie MA et al.
Plos Computational Biology, 2022
Sex differences in MEN 2A penetrance and expression according to parental inheritance.
Machens A et al.
European Journal of Endocrinology, 2022
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
Qi XP et al.
Bmc Cancer, 2021
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Ciampi R et al.
Iscience, 2019
RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.
Qi XP et al.
Thyroid : Official Journal of the American Thyroid Association, 2019
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.
Fanis P et al.
Journal of Endocrinological Investigation, 2018
Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A et al.
Human Mutation, 2018
Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.
Kaczmarek-Ryś M et al.
Endocrine-related Cancer, 2018
A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC et al.
Archives of Endocrinology and Metabolism, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.
Lennon P et al.
Irish Journal of Medical Science, 2017
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM et al.
Oncology, 2016
In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.
Heineman TE et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2015
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C et al.
Thyroid : Official Journal of the American Thyroid Association, 2012
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Waguespack SG et al.
Nature Reviews. Endocrinology, 2011
Variant identification in multi-sample pools by illumina genome analyzer sequencing.
Margraf RL et al.
Journal of Biomolecular Techniques : Jbt, 2011
Multi-sample pooling and illumina genome analyzer sequencing methods to determine gene sequence variation for database development.
Margraf RL et al.
Journal of Biomolecular Techniques : Jbt, 2010
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Romei C et al.
European Journal of Endocrinology, 2010
PhenoHM: human-mouse comparative phenome-genome server.
Sardana D et al.
Nucleic Acids Research, 2010
Multiple endocrine neoplasia type 2.
Lips CJ et al.
Expert Review of Endocrinology & Metabolism, 2009
Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L et al.
Journal of Internal Medicine, 2009
Familial prevalence and age of RET germline mutations: implications for screening.
Machens A et al.
Clinical Endocrinology, 2008
Pheochromocytoma penetrance varies by RET mutation in MEN 2A.
Machens A et al.
Surgery, 2008
The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland.
Paszko Z et al.
Cancer Investigation, 2007
Pheochromocytoma penetrance varies by RET mutation in MEN 2A.
Quayle FJ et al.
Surgery, 2007